| Name | ATN-161 trifluoroacetate salt |
| Description | ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases and improves survival in a murine model. |
| In vitro | The co-administration of ATN-161 and 5-FU markedly reduces tumor cell growth more effectively than either treatment alone or the control. Additionally, this combined approach markedly elevates the levels of apoptotic (TUNEL-positive) tumor cells, a result not observed with single-agent treatments. Furthermore, ATN-161 demonstrates a 21% reduction in endothelial cell (EC) numbers after 48 hours compared to controls, highlighting its effectiveness. Importantly, ATN-161 also impedes VEGF-induced endothelial cell migration and capillary formation, although it does not affect their proliferation. It significantly decreases endothelial cell migration towards VEGF in a dose-dependent manner, beginning at 100 nM (P<0.001 vs. VEGF group), showcasing its potential in inhibiting angiogenesis[1][2]. |
| In vivo | Initial tests on α5β1-negative human colon cancer xenografts (HT29) show ATN-161 significantly decreases tumor weight and vessel density [1]. Administering ATN-161 post-laser photocoagulation effectively suppresses choroidal neovascularization (CNV) leakage and new blood vessel formation, achieving results comparable to those with AF564 [2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 5.95 mg/mL (8.36 mM), Sonication is recommended.
DMSO : Slightly soluble
|
| Keywords | Integrin α5β1 | Integrin | Inhibitor | inhibit | ATN161 trifluoroacetate salt | ATN-161 Trifluoroacetate | ATN161 Trifluoroacetate | ATN-161 TFA | ATN-161 | ATN161 | ATN 161 trifluoroacetate salt | ATN 161 Trifluoroacetate | ATN 161 |
| Inhibitors Related | K34c hydrochloride | Cucurbitacin B | Tirofiban hydrochloride monohydrate | (R)-Leucic acid | Lifitegrast | Cyclo(-RGDfK) | ADH-503 | Elsibucol | CLT-28643 | Bestatin hydrochloride | Gantofiban | 2-hydroxy Flutamide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
